[ivory-search id="184" title="Recordati AJAX Search Form"]
Farfetch’d – 083/165 – Common – Reverse Holo – Near Mint

Farfetch’d – 083/165 – Common – Reverse Holo – Near Mint

USD 1.50 USD
SKU: plG3VaJV
GTIN: Does not apply
Condition: Ungraded
Tags: 083/165 Colorless Common Farfetch'd Pokémon Reverse Holo Scarlet & Violet 151
Categories: Collectible Card Games

Specifications

GamePokemon
SetScarlet & Violet - 151
Card Number083/165
RarityCommon
Card TypeColorless
NameFarfetch'd
FinishReverse Holo

What I appreciate about the card stock is its lack of a slick coating for a natural feel.

Related Items

Mela 254/182 SV04: Paradox Rift Holo
Mela 254/182 SV04: Paradox Rift Holo
 Palkia Full Art Promo XY75 XY Basic Pokémon Extended Art Case
Palkia Full Art Promo XY75 XY Basic Pokémon Extended Art Case
 Raticate – 020/165 – Uncommon – Reverse Holo – Near Mint
Raticate – 020/165 – Uncommon – Reverse Holo – Near Mint
 Whiscash 41/160 Rare Primal Clash Pokemon LP
Whiscash 41/160 Rare Primal Clash Pokemon LP
 Lugia Holo No.249 Neo Genesis – Japanese Pokemon Card – 2000
Lugia Holo No.249 Neo Genesis – Japanese Pokemon Card – 2000
 Crucible of Worlds (7162) Secret Lair Drop MTG Regular Near Mint
Crucible of Worlds (7162) Secret Lair Drop MTG Regular Near Mint
 Pokémon TCG Flygon V 087/127 CS5c RR Holo Chinese Dragon 220HP 2024
Pokémon TCG Flygon V 087/127 CS5c RR Holo Chinese Dragon 220HP 2024
 2025 S&V Destined Rivals Team Rocket’s Moltres ex Secret Rare #229/182
2025 S&V Destined Rivals Team Rocket’s Moltres ex Secret Rare #229/182

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site